Sodium-glucose cotransporter-2 (SGLT-2) inhibitor reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the efficacy of bodyweight reduction of SGLT-2 inhibitor in type 2 diabetic Korean patients. We evaluated the efficacy and safety of body weight reduction of SGLT-2 inhibitor in people with type 2 diabetes in Korea.


This is a retrospective, observational study, data from 56 patients with 12 months of SGLT-2 inhibitor(Dapagliflozin 10mg once-daily) therapy were analyzed, visited medical center from January 2015 to July 2016. We had divided into three treatment groups: first group taking combination of dapagliflozin and metformin(Group 1); second group taking triple combination of dapagliflozin and metformin with sulfonylurea(Group 2); third group taking quadriple combination of dapagliflozin, metformin and sulfonylurea with DPP-4inhibitors(Group 3).


Mean age and DM duration were 58.5±9.6 years and 11.4±5.6 years, re¬spectively, while mean body weight and baseline body mass index (BMI) were 72.6±12.1 kg and 27.3±3.6 kg/m2, respectively. More than half of the patients in our study were obese (60%, n=37). After 12 months, mean change from baseline body weight was -3.2±2.6 kg(P<0.001) for total, -3.4±3.1 kg(P<0.001) for group 1, -2.9±2.0 kg(P=0.008) for group 2,-4.0±2.3 kg(P<0.001) for group 3. In total, mean change from baseline SBP and DBP were -5.9±14 mmHg(P=0.001) and -3.2±7.7 mmHg(P=0.002) respectively. Patients who achieved body weight reduction of ≥5% after 12 months were classified in the responder group and<5% non-responder group. There were baseline fasting C-peptide level was higher in responder group than non-responder group(3.15±1.07ng/mL vs. 2.42±1.02 ng/mL, P=0.02). There were no serious adverse event including hypoglycemia in dapagliflozin group.


In patients with type 2 diabetes, Combination of SGLT-2 inhibitor reduced body weight reduction with safety.